IRIS
PASSAMONTI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.630
EU - Europa 1.800
AS - Asia 1.329
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 8
SA - Sud America 6
OC - Oceania 4
Totale 5.787
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.613
CN - Cina 1.184
IE - Irlanda 495
UA - Ucraina 378
FI - Finlandia 273
DE - Germania 206
SE - Svezia 143
IT - Italia 132
SG - Singapore 118
GB - Regno Unito 94
FR - Francia 36
CA - Canada 16
BE - Belgio 15
IN - India 11
MU - Mauritius 7
NL - Olanda 7
RU - Federazione Russa 7
EU - Europa 6
AU - Australia 4
LT - Lituania 4
PL - Polonia 3
RO - Romania 3
TR - Turchia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CL - Cile 2
CO - Colombia 2
GR - Grecia 2
HK - Hong Kong 2
IR - Iran 2
JP - Giappone 2
NG - Nigeria 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BR - Brasile 1
EG - Egitto 1
GE - Georgia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
MX - Messico 1
MY - Malesia 1
NO - Norvegia 1
Totale 5.787
Salva come PNG Salva come JPEG
Città #
Chandler 548
Dublin 495
Jacksonville 469
Nanjing 351
Boardman 188
Ashburn 139
Nanchang 135
Hebei 116
Princeton 112
Shenyang 109
Lawrence 108
Medford 102
Wilmington 102
Changsha 93
Singapore 93
Ann Arbor 84
Beijing 77
Jiaxing 69
Helsinki 61
New York 61
Tianjin 61
Hangzhou 52
Woodbridge 38
Shanghai 34
Milan 32
Norwalk 16
Brussels 15
Des Moines 14
Verona 14
Fairfield 13
Pavia 13
Los Angeles 12
Toronto 12
Auburn Hills 11
Seattle 9
Florence 8
Jinan 8
Kunming 8
Ningbo 8
Pune 7
Zhengzhou 7
Falls Church 6
Rome 6
Taizhou 6
Tappahannock 6
Dearborn 4
Genoa 4
Guangzhou 4
Nuremberg 4
Washington 4
Xi'an 4
Como 3
Falkenstein 3
Lanzhou 3
Paris 3
Pognano 3
Raffadali 3
Redwood City 3
Reston 3
Saint Paul 3
Santa Clara 3
Andover 2
Borås 2
Cartagena 2
Cedar Knolls 2
Dallas 2
Fuzhou 2
Gießen 2
Groningen 2
Herne 2
Hong Kong 2
Istanbul 2
Kemerovo 2
Lagos 2
Manchester 2
Monmouth Junction 2
Navi Mumbai 2
Perugia 2
Peschiera Borromeo 2
Prato 2
Redmond 2
The Bronx 2
Tokyo 2
Ventimiglia Di Sicilia 2
Ampang 1
Ardabil 1
Augusta 1
Baku 1
Baotou 1
Berlin 1
Bochnia 1
Brescia 1
Buffalo 1
Cairo 1
Cambridge 1
Chicago 1
Chongqing 1
Colombo 1
Curitiba 1
Dalian 1
Totale 4.044
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 96
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. 96
Looking for CALR mutations in familial myeloproliferative neoplasms 87
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 85
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 81
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 80
Blast phase of essential thrombocythemia: A single center study. 78
Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug 76
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinibversusbest available therapy 74
Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. 73
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons 73
Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders 72
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 72
JAK2 (V617F) mutation in healthy individuals 71
Clinical Predictors of Outcome in MPN. 70
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis 69
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. 69
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 68
ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA 67
Leukemia risk models in primary myelofibrosis: an International Working Group study. 67
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process 67
EFFICACY OF PIPOBROMAN IN THE TREATMENT OF POLYCYTHEMIA VERA: LONG TERM RESULTS IN 163 PATIENTS 65
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. 65
PDGFRB disease: right diagnosis to prolong survival 63
Looking for familial nodular lymphocyte-predominant Hodgkin lymphoma 63
EFFICACY OF A IDARUBICIN, ETOPOSIDE AND INTERMEDIATE-DOSE CYTARABINE ARABINOSIDE AS SALVAGE THERAPY IN RELAPSING OR RESISTANT UNFAVORABLE LYMPHOMA 62
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. 62
Balancing efficacy and safety of JAK inhibitors in myelofibrosis 62
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) 62
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 61
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 61
Exaggerated insect bite-like reaction in patients affected by oncohaematological diseases 60
Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. 59
Pityriasis roseaelike eruption during treatment with imatinib mesylate: Description of 3 cases 59
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 59
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 59
New generation small-molecule inhibitors in myeloproliferative neoplasms 59
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 58
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders 58
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 58
A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients 58
Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. 58
Leucemia mieloide cronica e sindromi mieloproliferative croniche 57
Clinical relevance of JAK2 (V617F) mutant allele burden 56
TREATMENT OF EARLY STAGE HODGKIN’S DISEASE WITH FOUR CYCLES OF ABVD FOLLOWED BY ADJUVANT RADIOTHERAPY: ANALYSIS OF EFFICACY AND LONG TERM TOXICITY 56
EX VIVO MANIPULATION OF HEMATOPOIETIC STEM CELLS FOR TRANSPLANTATION: THE POTENTIAL ROLE OF AMIFOSTINE.SEMINARS IN ONCOLOGY. 55
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment 55
Pomalidomide is active in the treatment of anemia associated with myelofibrosis 55
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders 55
Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-positive Diffuse Large B-cell Lymphomas 55
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 55
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making 54
Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history 54
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera 54
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 54
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 53
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report 53
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 53
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. 53
Myeloproliferative Neoplasms 52
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 52
Survival in young patients with intermediate-/high-risk myelofibrosis: Estimates derived from databases for non transplant patients 51
European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. 51
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 51
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 50
Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis 50
A gain-of-function mutation of JAK2 in myeloproliferative disorders 50
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. 49
Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies 48
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs 48
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients 48
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. 48
Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients 48
Mutational status of myeloproliferative neoplasms. 47
European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. 47
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. 47
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 47
TREATMENT OF POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA: THE ROLE OF PIPOBROMAN. 46
Ruxolitinib and survival improvement in patients with myelofibrosis 46
How to manage polycythemia vera 46
How I treat polycythemia vera. 46
Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia 45
LE NEOPLASIE MIELOPROLIFERATIVE PHILADELPHIA NEGATIVE 44
Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper 44
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment 44
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 44
RBC-transfusion guidelines update 43
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms 42
What are RBC-transfusion-dependence and -independence? 41
Primary leptomeningeal CNS lymphoma presenting as bilateral facial nerve palsy 41
Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations. 41
JAK inhibitor in CALR-mutant myelofibrosis. 41
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project 40
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas 40
It is time to change thrombosis risk assessment for PV and ET? 37
Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. 36
Leukemic transformation of polycythemia vera: a single center study of 23 patients 35
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders 35
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. 34
Disease anticipation in familial myeloproliferative neoplasms. 33
Totale 5.617
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.828
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.828
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020253 0 0 0 0 0 0 17 77 3 116 40 0
2020/2021702 99 73 13 76 7 90 5 100 28 96 94 21
2021/2022493 11 6 11 6 19 11 6 29 21 17 82 274
2022/20231.573 168 96 18 149 150 180 2 102 632 11 32 33
2023/2024537 79 92 16 48 34 157 3 33 4 11 15 45
2024/2025339 29 127 36 39 40 66 2 0 0 0 0 0
Totale 5.899